Everolimus: all 667 studies that test it
Page 1 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaNot yet recruitingNCT07865130Phase 1
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingNCT07739914Phase 3
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingNCT07634601Phase 2
- HORUS-Cytomegalovirus Open Proof-of-concept Exploratory TrialNot yet recruitingNCT07570433Phase 4
- A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular AnomaliesNot yet recruitingNCT07477548Phase 2
- Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)Not yet recruitingNCT07435584Phase 1/2
- Adjuvant Intensification for LARNot yet recruitingNCT07407517Phase 3
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingNCT07318324Phase 1
- Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline MutationsNot yet recruitingNCT07218575Phase 2/3
- Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal WomenRecruitingNCT07191353Phase 2
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingNCT07165418Phase 3
- The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory EpilepsyRecruitingNCT07095933Early Phase 1
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Phase 3
- An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular MalformationsRecruitingNCT07037238Phase 2
- Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular CarcinomaNot yet recruitingNCT06994572Phase 1
- Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in KoreaNot yet recruitingNCT06942156Phase 4
- EVR and EPO for Liver Transplant ToleranceRecruitingNCT06832189Phase 1
- RESTOR: PK/PD mTORi Inhibition in Older AdultsRecruitingNCT06658093Early Phase 1
- Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant PatientsRecruitingNCT06584773Phase 4
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
- Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsRecruitingNCT06472388Phase 2
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingNCT06382948Phase 3
- Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRecruitingNCT06317298Not applicable
- Everolimus Combined With PD-1 in Advanced Colorectal Cancer PatientsNot yet recruitingNCT06301386Phase 2
- Expanding Liver Transplant Immunosuppression Minimization Via EverolimusRecruitingNCT06280950Phase 2
- Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
- Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical TrialRecruitingNCT06126588Phase 2
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeRecruitingNCT05954442Phase 3
- Rapalog Pharmacology (RAP PAC) StudyRecruitingNCT05949658Phase 1
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingNCT05843253Phase 2
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingNCT04485559Phase 1
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNCT04199026Not applicable
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated RejectionRecruitingNCT03955172Not applicable
- Signal TrAnsduction Pathway Activity Analysis in OVarian cancERRecruitingNCT03458221Phase 2/3
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaEnrolling by invitationNCT02579044Phase 1/2
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver CancerEnrolling by invitationNCT02081755Phase 4
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
- Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney FunctionTerminatedNCT04258423Phase 3Results posted
- Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedNCT04066114Phase 1/2Results posted
- Everolimus Monotherapy as Immunosuppression After Liver TransplantTerminatedNCT04063865Phase 3Results posted
- A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for ResectionCompletedNCT03834740Early Phase 1Results posted
- Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingNCT03697408Phase 1/2Results posted
- Liver Transplantation With Tregs at UCSFTerminatedNCT03654040Phase 1/2Results posted
- Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.CompletedNCT03525834Phase 4Results posted
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationCompletedNCT03468478Phase 4Results posted
- Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain TumorsCompletedNCT03387020Phase 1Results posted
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE ScoreCompletedNCT03386539Phase 3Results posted
- Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) AlterationsTerminatedNCT03352427Phase 2Results posted
- A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorCompletedNCT03312738Phase 2Results posted
- Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsCompletedNCT03245151Phase 1/2Results posted
- Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT03176238Phase 3Results posted
- Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
- Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and BreastCompletedNCT03154281Phase 1Results posted
- A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT03070301Phase 2Results posted
- CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast CancerActive, not recruitingNCT03032406Phase 2Results posted
- RAD001 and Neurocognition in PTEN Hamartoma Tumor SyndromeCompletedNCT02991807Phase 1/2Results posted
- LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to ChemotherapyCompletedNCT02985125Phase 1/2Results posted
- Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal TransplantationTerminatedNCT02974686Phase 4Results posted
- Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant RecipientsCompletedNCT02954198Not applicableResults posted
- A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
- Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
- SCHEDULE Follow Up Visit 5-7 yrCompletedNCT02864706Phase 4Results posted
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in ChinaCompletedNCT02842749Phase 4Results posted
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results posted
- Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted
- Treg Therapy in Subclinical Inflammation in Kidney TransplantationCompletedNCT02711826Phase 1/2Results posted
- Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
- Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on EverolimusTerminatedNCT02539459Phase 2Results posted
- Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast CancerCompletedNCT02520063Phase 1/2Results posted
- Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
- Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeCompletedNCT02456857Phase 2Results posted
- Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results posted
- A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDCompletedNCT02451696Phase 2Results posted
- Impact of Everolimus on HIV Persistence Post Kidney or Liver TransplantCompletedNCT02429869Phase 4Results posted
- Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsCompletedNCT02352844Phase 2Results posted
- Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With EverolimusCompletedNCT02338609Phase 4Results posted
- Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232TCompletedNCT02332902Phase 2Results posted
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results posted
- Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT02283658Phase 2Results posted
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
- Phase II Study of Everolimus Beyond ProgressionTerminatedNCT02269670Phase 2Results posted
- Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine TumorCompletedNCT02246127Phase 3Results posted
- Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreTerminatedNCT02236572Phase 2Results posted
- Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial CancerCompletedNCT02228681Phase 2Results posted
- Everolimus for Cancer With TSC1 or TSC2 MutationCompletedNCT02201212Phase 2Results posted
- Everolimus for Children With Recurrent or Progressive EpendymomaCompletedNCT02155920Phase 2Results posted
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid CancerActive, not recruitingNCT02143726Phase 2Results posted
- S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerTerminatedNCT02137837Phase 3Results posted
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerCompletedNCT02120469Phase 1Results posted